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BRIEF DEFINITIVE REPORT
CD4 T cells have been divided into several sub-
sets as defined by their cytokine products and 
functions after their activation. These include, 
but are not limited to, Th1, Th2, and Th17 
cells. The initial two T cell subsets described 
were Th1 cells, which secrete IFN- and aid in 
the clearance of intracellular bacteria and viruses, 
and Th2 cells, which secrete IL-4 and IL-5 and 
help control extracellular pathogens. More re-
cently, Th17 cells have been described as a third 
Th cell type that express the transcription factor 
RORt and IL-17A, provide protection against 
fungi and various other extracellular bacteria, 
and are pathogenic T cells in the development 
of autoimmune inflammatory diseases (Zhu and 
Paul, 2008).
Discovery of the T cell subsets that produce 
IL-9 has expanded significantly in recent years. 
IL-9 was primarily studied as a product of Th2 
cells, and implicated as an important regula-
tory cytokine in the lung and the gastrointesti-
nal tract (Faulkner et al., 1997; Townsend et al., 
2000; Forbes et al., 2008). Schmitt et al. first 
reported that IL-9 production is dependent on 
the initial presence of IL-2, and is greatly in-
creased by the addition of TGF- in a dose-
dependent manner. They also observed that 
the addition of IL-4 to TGF- in T cell cul-
tures substantially enhanced T cell IL-9 pro-
duction (Schmitt et al., 1994). This finding has 
been recently reexamined by two groups who 
suggest that the T effector cells produced by 
TGF- and IL-4 may represent a unique sub-
set of T cells, as these cells do not express any 
of the known transcription factors for T cell 
differentiation, including T-bet, GATA-3, 
RORt, and FoxP3 (Dardalhon et al., 2008; 
Veldhoen et al., 2008). More recent work has 
shown that T cell–derived IL-9 may mediate 
immunosuppression. Adaptive T reg cells de-
rived from encephalogenic T cells produce IL-9 
(Liu et al., 2006), and our own studies have 
shown that IL-9 can be colocalized with T reg 
cells within the tolerant allograft and is func-
tionally important for allograft survival (Lu 
et al., 2006). Therefore, IL-9 is produced by 
T cells that play a role in both inflammation 
and immunosuppression.
In this report, the hierarchy of IL-9 pro-
duction by defined T cell subsets was compared. 
CORRESPONDENCE  
Randolph J. Noelle:  
rjn@dartmouth.edu
Abbreviations used: CNS, cen-
tral nervous system; EAE, ex-
perimental autoimmune 
encephalomyelitis; MC, mast 
cell; MOG, myelin oligoden-
drocyte peptide; qRT-PCR, 
quantitative real-time PCR.
IL-9 as a mediator of Th17-driven 
inflammatory disease
Elizabeth C. Nowak,1 Casey T. Weaver,2 Henrietta Turner,2  
Sakhina Begum-Haque,1 Burkhard Becher,3 Bettina Schreiner,3  
Anthony J. Coyle,4 Lloyd H. Kasper,1 and Randolph J. Noelle1
1Department of Microbiology and Immunology, Dartmouth Medical School and the Norris Cotton Cancer Center,  
Lebanon, NH 03756
2Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294
3Institute of Experimental Immunology, Department of Pathology, University Hospital of Zurich, 8057 Zurich, Switzerland
4Department of Autoimmunity and Inflammation, MedImmune, Gaithersburg, MD 20878
We report that like other T cells cultured in the presence of transforming growth factor 
(TGF) , Th17 cells also produce interleukin (IL) 9. Th17 cells generated in vitro with IL-6 
and TGF- as well as purified ex vivo Th17 cells both produced IL-9. To determine if IL-9 
has functional consequences in Th17-mediated inflammatory disease, we evaluated the 
role of IL-9 in the development and progression of experimental autoimmune encephalo-
myelitis, a mouse model of multiple sclerosis. The data show that IL-9 neutralization and 
IL-9 receptor deficiency attenuates disease, and this correlates with decreases in Th17 cells 
and IL-6–producing macrophages in the central nervous system, as well as mast cell num-
bers in the regional lymph nodes. Collectively, these data implicate IL-9 as a Th17-derived 
cytokine that can contribute to inflammatory disease.
© 2009 Nowak et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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which have been previously described to report the expres-
sion of RORt (Ivanov et al., 2006), and IL-17F–Thy1.1 mice. 
As shown, after RORC-GFP mice receive a CFA immuni-
zation, we see a significant amount of IL-9 production from 
these cells ex vivo as compared with an internal negative control 
of naive T cells from the same mice (Fig. 1 E). We also per-
formed the same experiment in IL-17F–Thy1.1 reporter 
mice with similar results. In addition, we further sorted IL-17F–
negative CD44hi T cells from these mice and observed that 
their capacity to produce IL-9 was less than the IL-17F–positive 
CD44hi T cells (Fig. S1).
In addition to IL-9 secretion, the expression of IL-9R was 
also evaluated on T cells. Previous work has extensively de-
scribed IL-9 as influencing MCs and macrophages; however, 
there are reports that its receptor is also expressed on effector but 
not naïve T cells (Cosmi et al., 2004; Knoops and Renauld, 
2004). As no monoclonal antibodies have been produced to 
mouse IL-9R, all of these data are based on mRNA expres-
sion profiling. To confirm and expand these results, quantita-
tive real-time PCR (qRT-PCR) was performed to quantify 
IL-9R mRNA in T cells skewed under Th1, Th2, and Th17 
conditions. The data show that Th2 and Th17 cells consis-
tently had the highest expression of IL-9R mRNA expres-
sion, whereas Th1 cells had minimal expression (Fig. 1 F). 
Thus, because of the fact that IL-9R is expressed on IL-9–
producing T cells, an autocrine impact of IL-9 on T cell dif-
ferentiation is possible.
IL-9 neutralization ameliorates EAE
EAE is one disease model in which Th17 cells are the princi-
ple mediators of the symptoms observed. To determine if IL-9 
contributes to Th17-mediated disease development, chronic 
EAE was induced in mice with myelin oligodendrocyte pep-
tide (MOG)35-55, CFA, and pertussis toxin while administrat-
ing either control Ig antibody or neutralizing IL-9 antibody 
beginning the day before immunization. IL-9 blockade con-
sistently delayed the onset of disease, and this difference was 
statistically significant. However, mice did ultimately succumb 
with the same disease severity as controls (Fig. 2 A).
Next, to determine if IL-9 blockade qualitatively altered the 
T cell response to MOG, T cell responses were monitored dur-
ing disease development. Mice were sacrificed at day 12 after 
the initial immunization, at which point all mice showed little 
or no signs of disease. At that time, CD4 T cells were purified 
from the peripheral lymph nodes. Upon analysis, no significant 
difference in MOG-specific IL-17A (Fig. 2 B) responsiveness 
by ELISPOT was observed. However, MOG-specific IL-9 
production was significantly enhanced in IL-9–treated mice 
(Fig. 2 C), suggesting a possible feedback enhancement of IL-9 
production caused by IL-9 blockade.
To assess the immune response in the CNS, qRT-PCR 
on spinal cord samples from naive mice, EAE mice treated 
with control Ig, and EAE mice treated with IL-9 antibody 
was performed (Fig. 2 D). The data show a consistent decrease 
in both IL-17A and IL-6 signals in the IL-9–treated mice but 
no effect on IFN-. These data suggest that IL-9 blockade 
To unequivocally address IL-9 production by Th17 cells, 
IL-17F reporter T cells were used and demonstrated IL-9 
production by purified Th17 cells. Given this observation, 
it was determined whether IL-9 played a functionally signifi-
cant role in the Th17-mediated disease experimental auto-
immune encephalomyelitis (EAE). The data show that IL-9 
neutralization and IL-9R deficiency attenuate disease, and 
this correlates with decreases in Th17 cells and IL-6–pro-
ducing macrophages in the central nervous system (CNS), as 
well as mast cell (MC) numbers in the regional lymph nodes. 
Collectively, these data implicate IL-9 as a Th17-derived 
cytokine that can contribute to inflammatory disease.
RESULTS AND DISCUSSION
Th17 cells produce IL-9
To confirm the observation of Schmitt et al. (1994) that 
TGF- can induce IL-9 production, we stimulated T cells 
with the indicated concentrations of TGF- and assessed their 
capacity to produce IL-9 after restimulation. As expected, we 
saw that TGF- can induce IL-9 expression in a dose-depen-
dent manner (Fig. 1 A). To further characterize IL-9 produc-
tion by various T cell subsets, cells were cultured under defined 
conditions known to induce a spectrum of T cell phenotypes. 
The data show that Th17 (TGF- + IL-6) cells and cells 
stimulated with TGF- + IL-4 produced similar amounts of 
IL-9 (Fig. 1 B). As previously reported, it is also shown that 
conditions that induce the differentiation of adaptive T reg 
cells (TGF- + IL-2) generate T cells that produce IL-9. Be-
cause the cells differentiated under adaptive T reg cell condi-
tions contain both Foxp3 and Foxp3+ T cells, Foxp3 reporter 
T cells were used to sort-purify both of these populations to 
determine their capacity to produce IL-9. The data show that 
both of these populations produce similar amounts of IL-9 
(Fig. 1 C). In general, the hierarchy of IL-9 production by 
the conditions prescribed in these studies suggests that adap-
tive T reg cells consistently produced more IL-9 than Th2 cells 
but less than cell-cultured T cells derived with TGF- and 
IL-4 or IL-6 (Th17).
Heterogeneity in T cell differentiation is inherent in the 
induction of adaptive T reg as well as Th17 cells. As had been 
executed with the adaptive T reg cell studies, T cells from 
IL-17F–Thy1.1 reporter mice (Lee et al., 2009) were cultured 
with TGF- + IL-6 and Th17 purified by magnetic sorting 
for Thy1.1. Because none of the existing monocloncal anti-
bodies to mouse IL-9 are suitable for assessing cytoplasmic 
fluorescence (Veldhoen et al., 2008), an IL-9 ELISA was used 
to determine IL-9 production. The data show that the IL-17F–
positive population (>95% Th17 cells) produced IL-9 after 
restimulation. Furthermore, the IL-17F–negative population 
(<1% Th17 cells) produced fourfold less IL-9 than the IL-17F–
positive population (Fig. 1 D). We have also performed this 
experiment an additional time using FACS sorting to obtain 
purities of >99% for both populations with similar results 
(unpublished data). To additionally confirm that IL-9 pro-
duction by Th17 is not solely an in vitro phenomenon, we 
also used FACS sorting of cells from RORC-GFP mice, 
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what was observed with neutralizing antibody. However, 
IL-9R–deficient mice consistently had decreased severity 
over time and this difference was statistically significant. This 
suggests IL-9 may exert an effect throughout the progression 
of disease (Fig. 3 A).
Because the initial priming of Th17 cells in IL-9–treated 
mice appears equivalent to controls in lymph node but de-
creased in the CNS, we sought to determine if the delay in 
disease severity in IL-9R–deficient mice may be caused by 
a decreased ability to traffic into the CNS. Recently, two 
preferentially attenuates Th17 responses. In addition, no dif-
ference in the mRNA expression of Ebi3, IL-10, IL-12a 
(p35), or IL-12 (p40) was observed (unpublished data).
IL-9R deficiency impairs multiple aspects of disease
The data show that IL-9 blockade delays the induction of 
EAE; however, these mice eventually progress to a similar 
extent as controls. To independently evaluate the role of 
IL-9, the development of EAE in IL-9R KO mice was evalu-
ated. IL-9R KO mice had delayed onset of disease, similar to 
Figure 1. Th17 cells produce IL-9. (A) T cells were stimulated in vitro with the indicated concentration of TGF- for 4 d. Cells were washed, counted, 
and restimulated in the presence of CD3/CD28 for 24 h before supernatants were collected for ELISA. Results show means ± SD of two independent 
experiments. (B) Effector T cells were generated in vitro under the indicated conditions for 4 d and were restimulated as in A. Results are representative of 
at least four independent experiments. (C) Cells from TGF- + IL-2 cultures were sorted based into FoxP3-GFP–positive and –negative subsets and  
restimulated as in A. Results are representative of four independent experiments. (D) T cells cultured under Th17 conditions were separated into IL-17F–
positive and –negative subsets based on Thy1.1 expression using MACS columns (percentages are shown). Representative purity of both populations is 
shown. Cells were restimulated as in A for IL-9 production. Results were pooled from two independent experiments, and a Student’s t test was performed 
to compare the samples. Means ± SD are shown. (E) RORC-GFP mice were immunized with MOG emulsified in CFA, and splenic T cells were harvested 7 d 
later for sorting into the indicated populations (percentages are shown). Cells were restimulated with PMA/ionomycin for 4 h before supernatant was 
collected for ELISA. Results show means ± SD of two independent experiments, and a Student’s t test was performed to compare the samples. (F) qRT-PCR 
from Th1, Th2, and Th17 cells and BM-MCs was performed for IL-9R expression. All samples were standardized to the expression of IL-9R by BM-MCs. 
Results are representative of three independent samples from each experimental group.
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phocytes was observed by CNS cell isolation. However, the 
numbers of IL-17A+ CD4 T cells and IL-6+ macrophages in 
the CNS were decreased in IL-9R KO mice (Fig. 4, A and B). 
In addition, IFN- responses were not significantly different 
between groups (unpublished data).
It has been reported that MC deficiency can decrease the 
severity of EAE (Secor et al., 2000), and that MC accumula-
tion in the regional lymph nodes accompanies disease devel-
opment (Tanzola et al., 2003). Given the fact that IL-9 is a 
growth and differentiation factor of MCs (Zhou et al., 2001), 
MC accumulation in immunized WT and IL-9R KO mice 
was determined during the development of EAE. First, there 
are no defects in MC numbers in naive IL-9R KO mice 
(Steenwinckel et al., 2007). Second, WT EAE-immunized 
mice had elevated MC numbers (Brenner et al., 1994). Third, 
no MC accumulation was observed in immunized IL-9R 
KO mice (Fig. 4 C). Hence, it appears that IL-9 is critical for 
groups have highlighted the importance of CCR6 expression 
during the initiation of EAE (Liston et al., 2009; Reboldi 
et al., 2009); therefore, we examined T cell responses in the 
lymph node on day 7 after immunization. In this case we 
consistently found that the initial induction of CCR6 is 
equivalent between WT and KO mice (Fig. 3 C). In addi-
tion, at late time points histochemistry performed on spinal 
cord samples indicated that lymphocyte infilitrates were also 
equivalent between these two groups (Fig. 3 B). This sug-
gests that IL-9 responsiveness is not necessary for trafficking 
of cells to the CNS.
To further characterize the immune response in the CNS 
as well as to determine the cellular sources of IL-17A and IL-6 
observed by qRT-PCR in IL-9–treated mice, flow cytom-
etry was performed on isolated lymphocytes from the brain 
and spinal cord of diseased WT and IL-9R KO mice. No 
significant difference in the total numbers of infiltrating lym-
Figure 2. Treatment with neutralizing anti–IL-9 antibody slightly delays EAE. (A) Mice were immunized for EAE and were treated with control Ig 
(n = 6) or IL-9 antibody (n = 6) i.p. every other day starting with day 1. Mice were scored for disease severity, and the mean ± SEM for each time point 
is indicated. Results are representative of three independent experiments. The p-value obtained by a Mann-Whitney U test is indicated. (B and C) CD4  
T cells from the peripheral lymph nodes of EAE-immunized mice were taken from each group at day 12 (score = 0 or 1 for all mice used) and stimulated 
with antigen-presenting cells and MOG for (B) IL-17A spot-forming units (SFU) in ELISPOTs or (C) IL-9 concentration in ELISA. Means ± SD are shown for 
both graphs. *, P < 0.05 from the control sample by a Student’s t test. Results shown are pooled from three independent experiments. (D) RNA was made 
from spinal cord samples of EAE-immunized mice from each group at the peak of disease severity in control mice, and the mean expression relative to  
-actin is shown. Results are representative of four naive, eight control, and eight IL-9–treated mice taken from three independent experiments.
JEM VOL. 206, August 3, 2009 1657
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eventually succumbed to the same extent as WT T cells → 
WT controls. However, the transfer of IL-9R KO T cells 
→ IL-9R KO hosts displayed both delayed onset and re-
duced severity of disease. Overall, these results suggest that 
IL-9R expression on both the encephalitogenic T cells and 
other host cell types contributes to the effect seen in IL-9R 
KO mice.
The findings presented establish (a) the hierarchy of IL-9 
production by differentiated T cell subsets and purified subsets 
derived from these cells, (b) that purified Foxp3+ adaptive T 
reg and Th17 cells produce IL-9, (c) that IL-9 contributes to 
the development of EAE, (d) that IL-9 influences the expres-
sion of IL-17A and IL-6 in the CNS, and (e) that IL-9 mediates 
the accumulation of MCs in the regional lymph nodes during 
the development of EAE. Collectively, the findings implicate 
IL-9 as a mediator of Th17-driven inflammatory diseases.
The data show that both Th17 and TGF- + IL-4 T cells 
produce high levels of IL-9 upon restimulation. Furthermore, 
Foxp3+ and Foxp3 T cells from in vitro generation of adap-
tive T reg cells also produce IL-9. To definitively show that 
Th17 cells produce IL-9, reporter Th17 cells were isolated 
and IL-9 production was confirmed. These results add to the 
growing list of IL-9–producing T cells, which includes natu-
ral T reg, adaptive T reg, and Th2 cells (Gessner et al., 1993; 
Schmitt et al., 1994; Hauber et al., 2004; Liu et al., 2006; Lu 
et al., 2006). In contrast, Veldhoen et al. (2008) reported that 
neither Th2, adaptive T reg, natural T reg, nor Th17 cells 
produce IL-9. The differences between that study and the 
findings in this paper, as well as others (Gessner et al., 1993; 
Schmitt et al., 1994; Hauber et al., 2004; Liu et al., 2006; Lu 
et al., 2006), has yet to be resolved.
In addition, the data show that IL-9 blockade by antibody 
or by IL-9R deficiency can ameliorate EAE. However, it must 
be noted that the phenotype of the IL-9R KO mice is much 
less robust than reported in IL-6 KO (Korn et al., 2007), IL-23 
(p19 and p40) KO (Becher et al., 2002; Cua et al., 2003), 
and RORt KO mice (Ivanov et al., 2006), which are com-
pletely protected from disease. Functionally, the data show 
that disease in IL-9R KO mice correlates with a reduction of 
IL-17A+ CD4 T cells and IL-6+ macrophages in the CNS of 
mice, as well as a decrease in MC numbers in the lymph 
nodes of mice. The later finding is not surprising, as IL-9 is 
known as a growth and activation factor for MCs (Faulkner 
et al., 1997; Townsend et al., 2000; Forbes et al., 2008). Ex-
tensive work performed by Melissa Brown’s group has also 
shown that MC-deficient W/Wv mice display suboptimal 
EAE (Secor et al., 2000; Tanzola et al., 2003; Gregory et al., 
2005), and we have observed a similar phenotype in MC-
deficient Wsh mice (unpublished data).
The findings presented, in the context of the emerging 
literature, establish that IL-9 cannot be readily assigned as being 
either a pro- or antiinflammatory cytokine. Rather, its func-
tion may be as an autocrine differentiation factor for inflam-
matory T cells and/or T reg cells, or as a paracrine factor 
regulating the activities of macrophages and/or MCs to me-
diate inflammation or suppression.
the inflammation-induced accumulation of MCs during dis-
ease development.
A functional role for IL-9 in encephalitogenic T cells 
was sought because differentiated Th17 cells express IL-9R 
mRNA. As such, adoptive transfer studies were performed 
using WT or IL-9R KO MOG-primed T cells. Further-
more, adoptive transfer of WT T cells into WT or IL-9R 
KO hosts was performed to address whether host expres-
sion of IL-9R was important to the development of disease 
(Fig. 4). The transfer of IL-9R KO T cells → WT and WT 
T cells → IL-9R KO hosts caused a slight delay in disease 
onset and reduced severity at early time points, but the mice 
Figure 3. IL-9R deficiency ameliorates the severity of EAE. (A) WT 
(n = 20) and KO (n = 21) mice were immunized for EAE and scored to gen-
erate graphs of mean disease score ± SEM. Results were pooled from three 
independent experiments, and a Mann-Whitney U test was performed to 
assess the p-value shown. (B) Transverse spinal cord sections of WT (n = 8) 
and KO (n = 8) mice from two independent experiments were taken to 
perform the hematoxylin and eosin staining shown. Bar, 200 µm. (C) On 
day 7 after EAE immunization, draining lymph nodes of WT and KO mice 
were taken and CD4 T cells were assessed for CD44 and CCR6 expression 
(percentages are shown). Results are representative of three independent 
experiments with four to six mice from each group per experiment.
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emulsified in CFA (Sigma-Aldrich) on day 0 and an i.p. injection of 400 ng 
pertussis toxin (Sigma-Aldrich) on days 0 and 2. Mice were scored daily 
as previously described (Becher et al., 2002). In some experiments, mice 
were also treated with 200 µg of control Ig or IL-9 (MM9C1) antibody 
(MedImmune) i.p. every other day starting the day before immunization. 
For adoptively transferred EAE, T cells from WT and KO mice on day 
14 after EAE induction were isolated and further cultured for 3 d in 
vitro to promote Th17 cell differentiation, as previously described (Ogura 
et al., 2008). Each mouse received 1.5–2 × 106 cells intravenously and 200 
ng pertussis toxin on the day of the cell transfer and 7 d after the initial 
immunization.
Histochemistry. Spinal cords from perfused mice with EAE were isolated. 
Transverse sections of spinal cords (5-µm) were cut and stained with hema-
toxylin and eosin. Photographs of the sections were taken at 20× magnifica-
tion using a microscope (BX41; Olympus).
MATERIALS AND METHODS
Mice. C57BL/6 mice were purchased from Charles River Laboratories. IL-9R–
deficient mice (Steenwinckel et al., 2007) were provided by J.-C. Renauld 
(Ludwig Institute, Brussels, Belgium) and were bred in-house. FoxP3-GFP 
reporter mice were bred in-house after being provided by A. Rudensky 
(University of Washington, Seattle, WA). Spleen cells from IL-17F–Thy1.1 
reporter mice were provided by C.T. Weaver (University of Alabama at 
Birmingham, Birmingham, AL) and have been previously described (Lee 
et al., 2009). RORC-GFP mice (Ivanov et al., 2006) were purchased from 
the Jackson Laboratory. All experiments using mice were performed in ac-
cordance with protocols approved by the Institutional Animal Care and Use 
Committee of Dartmouth College.
EAE induction and clinical evaluation. Age-matched female 
C57BL/6 and IL-9R KO mice that were 6–10 wk old were immunized 
subcutaneously with 200 µg of MOG35-55 peptide (Peptides International) 
Figure 4. IL-9R expression by both T cells and other cell types contributes to adoptively transferred EAE. (A and B) Lymphocytes from the 
brains and spinal cords of WT (n = 4) and KO (n = 4) mice were isolated, counted, and stained for (A) CD4 T cells and IL-17A and (B) macrophages and 
IL-6 after restimulation. The frequency of cytokine-producing cells by FACS was used to calculate the absolute numbers of cells shown. *, P < 0.01 by 
the Student’s t test. Results show means ± SD and are representative of three independent experiments. (C) Peripheral lymph nodes of mice were pooled 
and enriched for FCRI expression and stained for c-kit to identify MCs. Representative FACS plots are shown of WT and KO mice. Absolute numbers of 
MCs in lymph nodes were determined for WT naive (n = 5), KO naive (n = 5), WT EAE (n = 12), and KO EAE (n = 14) mice pooled from four independent 
experiments. A Student’s t test between the WT naive group and each other group was performed to assess statistical significance. Horizontal bars  
represent means. (D) T cells from WT and KO mice with EAE were transferred to either WT or KO mice to cause disease. Mice were scored and the mean 
disease scores ± SEM are shown. A Mann-Whitney U test was done to compare the WT T cell → WT group with each of the indicated groups to obtain 
the p-values shown. Results were pooled from two independent experiments, and the numbers of mice used are as follows: WT T cell → WT, n = 16;  
KO T cell → WT, n = 15; WT T cell → KO, n = 14; and KO T cell → KO, n = 12.
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